Stocks · News reference
Jefferies analyst Biren Amin upgrades Minerva Neurosciences (NASDAQ:NERV) from Hold to Buy and raises the price target from $7.5 to $10.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Minerva Neurosciences announced it will host an in-person and virtual event on November 12, 2026, featuring management and key opinion leaders to discuss the clinical opportunity for roluperidone.
Minerva Neurosciences announced participation in two upcoming investor conferences (Wells Fargo Healthcare Conference on September 8 and Cantor Global Healthcare Conference on September 9, 2026). The company is conducting a confirmatory Phase 3 trial of roluperidone for negative symptoms of schizophrenia, with topline efficacy data expected in the second half of 2027. The company has also established a Scientific Advisory Board of leading experts in psychiatry and neuroscience.
Wall Street analysts revised their ratings for top stocks. Visit benzinga.com/analyst-stock-ratings for all changes, including upgrades and downgrades.